APA (7th ed.) Citation

JS, H., C, T., M, M., A, N., T, H., SM, R., . . . JS, W. (2023). Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency. Nature communications, 14(1), 5032. https://doi.org/10.1038/s41467-023-40758-0

Chicago Style (17th ed.) Citation

JS, Heitmann, et al. "Phase I/II Trial of a Peptide-based COVID-19 T-cell Activator in Patients with B-cell Deficiency." Nature Communications 14, no. 1 (2023): 5032. https://doi.org/10.1038/s41467-023-40758-0.

MLA (9th ed.) Citation

JS, Heitmann, et al. "Phase I/II Trial of a Peptide-based COVID-19 T-cell Activator in Patients with B-cell Deficiency." Nature Communications, vol. 14, no. 1, 2023, p. 5032, https://doi.org/10.1038/s41467-023-40758-0.